Skip to main content

Table 5 The league table for SAE estimates interventions according to their relative effects in first part network analysis

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Apatoren+Taxane (49.6%)#      
−0.21 (−2.02,1.61)Icrucumab+Taxane (38.5%)     
−0.25 (−2.00,1.51)− 0.04 (− 1.85,1.77)Pazopanib (36.7%)    
0.18 (−1.36,1.73)0.39 (−0.98,1.76)0.43 (−1.11,1.97)Ramucirumab+Taxane (59.7%)   
0.47 (−0.77,1.71)0.68 (−0.64,2.00)0.72 (− 0.52,1.96)0.29 (− 0.63,1.21)Taxane (79.8%)  
−0.50 (−2.25,1.24)− 0.29 (− 2.10,1.51)−0.26 (− 2.00,1.49)−0.69 (− 2.22,0.85)−0.98 (− 2.20,0.25)Vandetanib+Taxane (24.7%) 
0.24 (− 1.62,2.11)0.45 (− 1.47,2.37)0.49 (− 1.37,2.35)0.06 (− 1.61,1.73)− 0.23 (− 1.62,1.16)0.75 (− 1.11,2.60)Vinflunine (61.1%)
  1. SAE Severe adverse effect
  2. aThe SUCRA probabilities are performed in brackets